BDP9066

BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.

Product Specifications

CAS Number

[2226507-04-4]

UNSPSC

12352005

Target

Cdc42-binding kinase

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BDP9066.html

Purity

98.49

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

C12=C(N3CCC[C@@]4(CCCCN4)C3)C=CNC1=NC=C2C5=NC=NC=C5

Molecular Formula

C20H24N6

Molecular Weight

348.44

References & Citations

[1]Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78 (8) :2096-2114.